New combo pill targets cholesterol in metabolic syndrome patients
NCT ID NCT07523971
First seen Apr 17, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study is testing a combination pill (Pitavastatin/Ezetimibe) to lower cholesterol in 10,000 adults who have both high cholesterol and metabolic syndrome. Researchers will measure how much LDL-C (bad cholesterol) drops after 24 and 48 weeks, and check for side effects. Participants receive standard care, and the goal is to see how well the pill works in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chungnam National University Hospita
RECRUITINGDaejeon, South Korea
Conditions
Explore the condition pages connected to this study.